title: Angioimmunoblastic T cell lymphoma: an unusual presentation of posttransplant lymphoproliferative disorder in a pediatric patient.
abstract: Posttransplant lymphoproliferative disorders (PTLD) are a potentially life-threatening complication of immunosuppression in transplant recipients. The majority of cases are Epstein-Barr virus-associated lesions of B cell origin. T cell PTLD is rare, particularly in pediatric patients. We present an unusual case of monomorphic T cell PTLD with features of angioimmunoblastic T cell lymphoma in an 8-year-old heart transplant patient, presenting with cranial nerve palsy.
authors.affiliation: Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Okla., USA.
authors.forename: Teresa S
authors.initials: TS
authors.lastname: Kraus
authors.forename: Clare J
authors.initials: CJ
authors.lastname: Twist
authors.forename: Brent T
authors.initials: BT
authors.lastname: Tan
mesh_terms: D000542:Alveolitis, Extrinsic Allergic / Q000150:complications / Q000188:drug therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D016027:Heart Transplantation; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy / Q000209:etiology*; D016867:Immunocompromised Host; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007619:Kartagener Syndrome / Q000150:complications; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000209:etiology*; D008727:Methotrexate / Q000008:administration & dosage; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015840:Oculomotor Nerve Diseases / Q000209:etiology; D011183:Postoperative Complications / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000473:pathology; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007166:Immunosuppressive Agents; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D011241:Prednisone; D006854:Hydrocortisone; D016559:Tacrolimus; D008727:Methotrexate